z-logo
open-access-imgOpen Access
Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients
Author(s) -
Rongcai Jiang,
Shiguang Zhao,
Renzhi Wang,
Hua Feng,
Jianmin Zhang,
Xingang Li,
Ying Mao,
Xianrui Yuan,
Zhou Fei,
Yuanli Zhao,
Xinguang Yu,
Wai Sang Poon,
Xide Zhu,
Ning Liu,
Dezhi Kang,
Tao Sun,
Baohua Jiao,
Xianzhi Liu,
Rutong Yu,
Junyi Zhang,
Guodong Gao,
Jie-he Hao,
Ning Su,
Gangfeng Yin,
Xingen Zhu,
Yicheng Lu,
Junji Wei,
Jin Hu,
Rong Hu,
Jiànróng Lǐ,
Dong Wang,
Huijie Wei,
Ye Tian,
Ping Lei,
Jingfei Dong,
Jianning Zhang
Publication year - 2018
Publication title -
jama neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.298
H-Index - 231
eISSN - 2168-6157
pISSN - 2168-6149
DOI - 10.1001/jamaneurol.2018.2030
Subject(s) - medicine , glasgow coma scale , atorvastatin , hematoma , placebo , chronic subdural hematoma , randomized controlled trial , surgery , midline shift , pathology , alternative medicine
Chronic subdural hematoma (CSDH) is a trauma-associated condition commonly found in elderly patients. Surgery is currently the treatment of choice, but it carries a significant risk of recurrence and death. Nonsurgical treatments remain limited and ineffective. Our recent studies suggest that atorvastatin reduces hematomas and improves the clinical outcomes of patients with CSDH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom